Xenon Pharmaceuticals Azioni (NASDAQ: XENE)

Ultime notizie per Xenon Pharmaceuticals (NASDAQ:XENE) Azioni

Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals Inc

Xenetic Biosciences Inc

Xenetic Biosciences Inc Warrants (19/07/2024)

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $53 price target.

News

Price Target

Reiteration

Analyst Ratings

XENE

HC Wainwright & Co. Reiterates Buy on Xenon Pharmaceuticals, Maintains $53 Price Target

Needham analyst Serge Belanger reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $60 price target.

Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $60 Price Target

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.81) per share which met the analyst consensus estimate.

Earnings

Xenon Pharmaceuticals Q3 2024 GAAP EPS $(0.81), Inline

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-12. Here's what investors need to know before the announcement.
Analysts estimate that Xenon Pharmaceuticals will report an earnings per share (EPS) of $-0.83. 
The market awaits Xenon Pharmaceuticals's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.05, leading to a 3.19% drop in the share price on the subsequent day.
Here's a look at Xenon Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.70</td>
<td>-0.66</td>
<td>-0.76</td>
<td>-0.77</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.75</td>
<td>-0.62</td>
<td>-0.64</td>
<td>-0.73</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>-1.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731333676_0.png" alt="eps graph" />
<h3>Market Performance of Xenon Pharmaceuticals's Stock</h3>
Shares of Xenon Pharmaceuticals were trading at $45.0 as of November 07. Over the last 52-week period, shares are up 51.26%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/XENE/earnings">To track all earnings releases for Xenon Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Xenon Pharmaceuticals

Raymond James analyst Danielle Brill reinstates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and announces $50 price target.

Initiation

Raymond James Reinstates Outperform on Xenon Pharmaceuticals, Announces $50 Price Target

HC Wainwright &amp; Co. analyst Douglas Tsao initiates coverage on Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy rating and announces Price Target of $53.

HC Wainwright & Co. Initiates Coverage On Xenon Pharmaceuticals with Buy Rating, Announces Price Target of $53

RBC Capital analyst Brian Abrahams reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and maintains $55 price target.

RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target

Xenon Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company's pipeline of small molecule programs with a focus on preparation for the commercial launch of azetukalner.

Management

Xenon Expands Leadership Team With Matthew D. Ronsheim as Chief Operating Officer

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $62 to $60.

Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60

Cantor Fitzgerald analyst Josh Schimmer reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Overweight and maintains $65 price target.

Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and lowers the price target from $50 to $49.

Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $49

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.70) by 7.14 percent.

Earnings Misses

Xenon Pharmaceuticals Q2 2024 GAAP EPS $(0.75) Misses $(0.70) Estimate

Biotech

Events

General

Xenon Pharmaceuticals Presents Phase 2 X-NOVA Clinical Trial Data Of Azetukalner in Major Depressive Disorder At ASCP 2024 Annual Meeting

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $62 price target.

Needham Maintains Buy on Xenon Pharmaceuticals, Maintains $62 Price Target

Citigroup analyst David Hoang maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $62 to $60.

Citigroup Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and lowers the price target from $51 to $50.

Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $50

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.66) by 6.06 percent.

Earnings Beats

Xenon Pharmaceuticals Q1 2024 Adj EPS $(0.62) Beats $(0.66) Estimate

Xenon's Oral Presentations at AAN
Oral Presentation #005 (French et al.) "Interim, Long-term, Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults with Focal Epilepsy." Session 19: Epilepsy Clinical Trials and Long-term Studies Oral Presentation #004 (Porter et al.) "The Impact of Disease Severity on Responder Rates in a Phase 2b Study of XEN1101, a Potent, Selective Potassium Channel Opener, in Adults With Focal Epilepsy (X-TOLE)." Session 19: Epilepsy Clinical Trials and Long-term Studies
Xenon is also hosting Booth #1797 in the AAN Exhibit Hall, which runs until Wednesday, April 17, 2024 at 4:00 pm MT.

Xenon Pharmaceuticals Announced Two Oral Presentations For XEN1101 Clinical Data At AAN 2024 Annual Meeting

Xenon Pharma Q3 2024 Earnings Preview

Xenon Pharma GAAP EPS of -$0.81 in-line

"Xenon's leadership in the Kv7 landscape is unmatched as our lead molecule, azetukalner, represents the only highly potent, selective Kv7 potassium...

Xenon Pharmaceuticals reports Q3 EPS (81c), consensus (81c)

TD Cowen analyst Joseph Thome maintained a Buy rating on Xenon (XENE – Research Report) yesterday. The company's shares closed yesterday at $43.39....

TD Cowen Keeps Their Buy Rating on Xenon (XENE)

Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript

Xenon Pharmaceuticals ( ($XENE) ) has released its Q3 earnings. Here is a breakdown of the information Xenon Pharmaceuticals presented to its inves...

Xenon Pharmaceuticals Reports Q3 2024 Progress and Outlook

Xenon (XENE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal from Wells Fa...

Promising Growth Ahead: Xenon's Strategic Pipeline Advancements and Buy Rating

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Xenon (XENE – Research Report), with a price target of $62...

Stifel Nicolaus Reaffirms Their Buy Rating on Xenon (XENE)

JPMorgan's 'Analyst Focus List' – growth, income, value, short ideas

We're only 6 weeks away from 2025, which means that it's time to check in again with Wall Street's investment banks and professional analysts – the...

JPMorgan Selects These 2 Stocks as Must-Haves for 2025

AGCO

ALRM

AMZN

ARMK

ASND

AVGO

BRBR

CVNA

CYBR

DAWN

DELL

DKNG

EWTX

GWRE

HASI

ISRG

KLAC

KVUE

LEGN

MNDY

MSFT

NTRA

PODD

ROIV

RVMD

SCHW

SIRI

SNDX

SPGI

SWTX

TFII

TMUS

TRGP

TVTX

ULTA

VICI

Press Releases

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Xenon to Report Q2 2024 Financial Results on August 8, 2024

Xenon Reports Q2 2024 Financial Results and Business Update

Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer

Comments

Xenon Pharmaceuticals

Notizie

Ultime notizie per Xenon Pharmaceuticals (NASDAQ:XENE) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO